Cellectis (NASDAQ:CLLS) Stock Rating Lowered by StockNews.com

Cellectis (NASDAQ:CLLS) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

Cellectis Stock Down 3.1 %

Shares of Cellectis stock opened at $1.27 on Wednesday. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The firm has a market cap of $70.59 million, a P/E ratio of -0.98 and a beta of 3.27. Cellectis has a fifty-two week low of $1.14 and a fifty-two week high of $3.38. The business has a 50-day moving average price of $1.46 and a 200 day moving average price of $1.79.

Cellectis (NASDAQ:CLLS) last issued its earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.22). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $33.22 million during the quarter, compared to analyst estimates of $5.90 million. On average, sell-side analysts forecast that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Wells Fargo & Company MN raised its stake in Cellectis by 103.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 12,500 shares during the period. Millennium Management LLC acquired a new stake in Cellectis during the 4th quarter valued at $962,000. Finally, B Group Inc. acquired a new stake in Cellectis during the 4th quarter valued at $5,547,000. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.